Bret Scholtes acted as the CEO and President of Guardion Health Sciences from January 2021 until June 2023. He came with a solid background in finance, armed with an MBA from New York University and an accounting degree from the...

Bret Scholtes acted as the CEO and President of Guardion Health Sciences from January 2021 until June 2023. He came with a solid background in finance, armed with an MBA from New York University and an accounting degree from the University of Missouri. Before Guardion, he led Omega Protein Corporation for nearly a decade, building his skills in corporate development and finance. Scholtes wasn't just leading from behind; he made a significant mark with his hands-on approach to executive role, focusing on performance and company growth. His compensation saw a wild swing, from earning nearly $1.68 million in 2021 to just $411,000 in 2022, showing how quickly situations can change in the corporate world. Interestingly, he was on the insider trading radar, with notable trades starting from January 2021 through 2024, indicating his deep involvement with the company's stock. Overall, his transition represents the typical roller coaster of executive positions in companies facing challenges and opportunities.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Guardion Health Sciences CEOs

G

Bret Scholtes

Ex-CEO of Guardion Health Sciences

Education

MBA degree in Finance from New York University and a degree in Accounting from the University of Missouri – Columbia

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

CEO of Guardion Health Sciences for

2 years 5 months (Jan 2021 - Jun 2023)

Previous Experience

President and Chief Executive Officer of Omega Protein Corporation

Rivals

Competitors/colleagues of Bret Scholtes

Holdings

See how much did Bret Scholtes make over time.

Bret Scholtes’ insider trading activity shows he was heavily involved in trading Guardion Health Sciences shares during his time as CEO. Starting January 2021, he consistently bought shares, steadily increasing his holdings, reaching peak transactions in early 2021, with stakes...

Bret Scholtes’ insider trading activity shows he was heavily involved in trading Guardion Health Sciences shares during his time as CEO. Starting January 2021, he consistently bought shares, steadily increasing his holdings, reaching peak transactions in early 2021, with stakes worth over $300K in February. His trading patterns shifted in 2022, becoming more modest, with monthly trades averaging around $44K by the end of the year. This represented a significant decrease from his previous activity. By 2023, Scholtes continued to sell smaller amounts, occasionally hitting over $40K per month. The fluctuations in his trading activities illustrate the challenges and strategic decisions that come with leading a company in the healthcare sector.

Insider Trading

See recent insider trades of Bret Scholtes.

GHSI

$12.43K

GHSI at $1.24/share

Aug 30, 2021

Purchase

GHSI

916,023 shares

GHSI

Jan 6, 2021

Received

GHSI

152,671 shares

GHSI

Jan 6, 2021

Received

Compensation History

See how much did Bret Scholtes make over time.

In his first year as CEO at Guardion Health Sciences, Bret Scholtes earned a total compensation of approximately $1,678,399, thanks to a hefty bonus of $280,000 based on performance. This was a significant difference compared to 2022, where his earnings dropped to just $411,000, reflecting no bonuses, stock awards, or additional compensation that year. The salary cut highlights the ups and downs of corporate leadership and how closely linked compensation can be to company performance and individual contributions. Scholtes’ contract included a target bonus, which indicates that his financial rewards were intended to align his interests with the company's success. Overall, his compensation reflects both the challenges of his role and the potential for substantial reward in a successful year.

Year

2022

Total Compensation

$411.00K

Salary

$411.00K

Board Justification

The compensation philosophy aims to align executive compensation with company performance and individual contributions, ensuring competitive pay to attract and retain top talent.

Bonus

$0.00

Board Justification

No bonus was awarded for the year 2022.

Other

$0.00

Board Justification

No other compensation was reported for 2022.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock awards vested in 2022.

Performance Metrics

Performance metrics for determining compensation were based on company and individual performance objectives.

Other Guardion Health Sciences CEOs

Here are other CEOs of Guardion Health Sciences

David Evans

Ex-CEO of Guardion Health Sciences

June 2020 - January 2021

Janet Hall

Ex-CEO of Guardion Health Sciences

June 2023 - October 2024